PacBio and Berry Genomics Announce Collaboration to Bring Long-Read Desktop Sequencers to the Chinese Clinical Market

New collaboration builds on two companies' existing relationship to develop desktop systems for the Chinese clinical market

Berry Genomics to purchase at least 50 instruments at launch

MENLO PARK, Calif.

The cooperation between the two companies includes development, regulatory authorization, production and distribution

"Bringing the power and accuracy of PacBio's long-read HiFi sequencing to the table offers Chinese customers the potential to understand the latest research and clinical applications," said Christian Henry, CEO and President of PacBio

This new collaboration builds on the early success of the two companies' 2019 agreement in which Berry Genomics supported regulatory approval of the PacBio Sequel II instrument for clinical use in China and sold the instrument and consumables

"PacBio and Berry Genomics have had great success with the Sequel II instrument in China," said Dr.

California-based Pacific Biosciences (NASDAQ: PACB) is providing life scientists with a high-precision sequencing platform

PacBio products are for research use only

Founded in May 2010, Berry Genomics is a leading company in clinical genomics and life sciences in China

As a company with strong R&D capabilities, Berry Genomics took the lead in launching NIPT, a genetic testing technology based on ngs, in China as early as 2010

With approximately 1,500 employees, Berry Genomics develops products and provides services to more than 4,000 institutions and facilities at home and abroad, including hospitals, research institutions, universities and businesses

Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 21E of the US Private Securities Litigation Reform Act of 1995, including information regarding future availability , date of publication, use, accuracy, advantages, quality or performance of PacBio's products or technologies, or the benefits or anticipated benefits of using such products or technologies, their suitability or utility for a particular application or project, including in Clinical applications in China and other non-US jurisdictions; anticipated purchase of PacBio benchtop sequencing systems in development; anticipated regulatory approvals and footprint expansion in certain markets in China; unlocking potential for new applications for Chinese clients; access to additional laboratories and potential for greater impact in the Chinese market; and other future events

Investor Contact: Todd Friedman, ir@pacificbiosciences.

Media: Kathy Lynch pr@pacificbiosciences.

Harry Liu Liuhui1@berrygenomics.